{"nctId":"NCT00518713","briefTitle":"Clobazam in Patients With Lennox-Gastaut Syndrome","startDateStruct":{"date":"2007-08"},"conditions":["Epilepsy","Epilepsy, Generalized","Seizures"],"count":238,"armGroups":[{"label":"Clobazam Low Dose","type":"EXPERIMENTAL","interventionNames":["Drug: Clobazam Low Dose"]},{"label":"Clobazam Medium Dose","type":"EXPERIMENTAL","interventionNames":["Drug: Clobazam Medium Dose"]},{"label":"Clobazam High Dose","type":"EXPERIMENTAL","interventionNames":["Drug: Clobazam High Dose"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Clobazam Low Dose","otherNames":["Onfi™"]},{"name":"Clobazam Medium Dose","otherNames":["Onfi™"]},{"name":"Clobazam High Dose","otherNames":["Onfi™"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient must have been \\<11 years of age at the onset of LGS.\n* Patient must have LGS.\n* Patient must be on at least 1 AED.\n* Parent or caregiver must be able to keep an accurate seizure diary.\n\nExclusion Criteria:\n\n* Etiology of patient's seizures is a progressive neurologic disease. Patients with tuberous sclerosis will not be excluded from study participation, unless there is a progressive tumor.\n* Patient has had an episode of status epilepticus within 12 weeks of baseline.\n* Patient has had an anoxic episode requiring resuscitation within 6 months of screening.\n* Patient has a clinically significant history of an allergic reaction or significant sensitivity to benzodiazepines.\n* Patient is taking more than 3 concurrent AEDs.\n* Patient has been on the ketogenic diet for less than 30 days prior to screening or suffers from frequent stooling.\n* If the patient has a Vagal Nerve Stimulator (VNS), the settings have not been stable for at least 30 days prior to screening.\n* Patient has taken corticotropins in the 6 months prior to screening.\n* Patient is currently taking long-term systemic steroids (excluding inhaled mediation for asthma treatment) or any other daily medication known to exacerbate epilepsy. An exception will be made of prophylactic medication, for example, for idiopathic nephrotic syndrome or asthma.\n* If the patient is taking felbamate, has been taking it for less than 1 year prior to screening.\n\nOther protocol-defined inclusion and exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","maximumAge":"60 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Reduction in Number of Drop Seizures (12-week Maintenance Period).","description":"Number of drop seizures (average per week) was obtained from seizure diaries. The average drop in seizures per week for patients who did not complete the maintenance period was calculated based on the time from the beginning of the maintenance period to date of withdrawal.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.2","spread":null},{"groupId":"OG001","value":"49.4","spread":null},{"groupId":"OG002","value":"68.3","spread":null},{"groupId":"OG003","value":"12.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Reduction in Number of Drop Seizures (First 4 Weeks of the 12-week Maintenance Period).","description":"Number of drop seizures (average per week) was obtained from seizure diaries. The average drop in seizures per week for patients who did not complete the maintenance period was calculated based on the time from the beginning of the maintenance period to date of withdrawal.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.8","spread":null},{"groupId":"OG001","value":"58.9","spread":null},{"groupId":"OG002","value":"71.0","spread":null},{"groupId":"OG003","value":"18.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Reduction in Number of Drop Seizures (Middle 4 Weeks of the 12-week Maintenance Period).","description":"Number of drop seizures (average per week) was obtained from seizure diaries. The average drop in seizures per week for patients who did not complete the maintenance period was calculated based on the time from the beginning of the maintenance period to date of withdrawal.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.1","spread":null},{"groupId":"OG001","value":"38.8","spread":null},{"groupId":"OG002","value":"64.9","spread":null},{"groupId":"OG003","value":"21.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Reduction in Number of Drop Seizures (Last 4 Weeks of the 12-week Maintenance Period).","description":"Number of drop seizures (average per week) was obtained from seizure diaries. The average drop in seizures per week for patients who did not complete the maintenance period was calculated based on the time from the beginning of the maintenance period to date of withdrawal.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.8","spread":null},{"groupId":"OG001","value":"56.0","spread":null},{"groupId":"OG002","value":"68.0","spread":null},{"groupId":"OG003","value":"-0.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Patients Considered Treatment Responders Defined as Those With a >=25%, >=50%, >=75%, 100% Reduction in Drop Seizures (12-week Maintenance Period).","description":"Number of drop seizures (average per week) was obtained from seizure diaries. The average drop in seizures per week for patients who did not complete the maintenance period was calculated based on the time from the beginning of the maintenance period to date of withdrawal.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"46","spread":null},{"groupId":"OG002","value":"41","spread":null},{"groupId":"OG003","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"34","spread":null},{"groupId":"OG002","value":"38","spread":null},{"groupId":"OG003","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"31","spread":null},{"groupId":"OG003","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"12","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Patients Considered Treatment Responders Defined as Those With a >=25%, >=50%, >=75%, 100% Reduction in Drop Seizures (First 4 Weeks of the 12-week Maintenance Period).","description":"Number of drop seizures (average per week) was obtained from seizure diaries. The average drop in seizures per week for patients who did not complete the maintenance period was calculated based on the time from the beginning of the maintenance period to date of withdrawal.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.7","spread":null},{"groupId":"OG001","value":"82.8","spread":null},{"groupId":"OG002","value":"89.8","spread":null},{"groupId":"OG003","value":"52.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.2","spread":null},{"groupId":"OG001","value":"72.4","spread":null},{"groupId":"OG002","value":"77.6","spread":null},{"groupId":"OG003","value":"31.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.8","spread":null},{"groupId":"OG001","value":"44.8","spread":null},{"groupId":"OG002","value":"63.3","spread":null},{"groupId":"OG003","value":"14.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.2","spread":null},{"groupId":"OG001","value":"19.0","spread":null},{"groupId":"OG002","value":"30.6","spread":null},{"groupId":"OG003","value":"3.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Patients Considered Treatment Responders Defined as Those With a >=25%, >=50%, >=75%, 100% Reduction in Drop Seizures (Middle 4 Weeks of the 12-week Maintenance Period).","description":"Number of drop seizures (average per week) was obtained from seizure diaries. The average drop in seizures per week for patients who did not complete the maintenance period was calculated based on the time from the beginning of the maintenance period to date of withdrawal.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.2","spread":null},{"groupId":"OG001","value":"65.5","spread":null},{"groupId":"OG002","value":"75.5","spread":null},{"groupId":"OG003","value":"50.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.4","spread":null},{"groupId":"OG001","value":"51.7","spread":null},{"groupId":"OG002","value":"71.4","spread":null},{"groupId":"OG003","value":"24.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.3","spread":null},{"groupId":"OG001","value":"34.5","spread":null},{"groupId":"OG002","value":"59.2","spread":null},{"groupId":"OG003","value":"12.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4","spread":null},{"groupId":"OG001","value":"15.5","spread":null},{"groupId":"OG002","value":"26.5","spread":null},{"groupId":"OG003","value":"5.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Patients Considered Treatment Responders Defined as Those With a >=25%, >=50%, >=75%, 100% Reduction in Drop Seizures (Last 4 Weeks of the 12-week Maintenance Period).","description":"Number of drop seizures (average per week) was obtained from seizure diaries. The average drop in seizures per week for patients who did not complete the maintenance period was calculated based on the time from the beginning of the maintenance period to date of withdrawal.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.0","spread":null},{"groupId":"OG001","value":"60.3","spread":null},{"groupId":"OG002","value":"71.4","spread":null},{"groupId":"OG003","value":"43.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.3","spread":null},{"groupId":"OG001","value":"50.0","spread":null},{"groupId":"OG002","value":"67.3","spread":null},{"groupId":"OG003","value":"29.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.3","spread":null},{"groupId":"OG001","value":"36.2","spread":null},{"groupId":"OG002","value":"57.1","spread":null},{"groupId":"OG003","value":"12.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.2","spread":null},{"groupId":"OG001","value":"15.5","spread":null},{"groupId":"OG002","value":"20.4","spread":null},{"groupId":"OG003","value":"5.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Tolerance","description":"Study responders who have ≥50% reduction in their drop seizure rate during the first 4 or first 8 weeks of maintenance compared to the 4 week baseline period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"42","spread":null},{"groupId":"OG002","value":"38","spread":null},{"groupId":"OG003","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"38","spread":null},{"groupId":"OG002","value":"38","spread":null},{"groupId":"OG003","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Investigator Global Evaluations of the Patient's Overall Change in Symptoms.","description":"The physician was asked to rate the patient's overall change in symptoms and overall change in seizure activity and Quality of Life since the beginning of clobazam treatment by checking \"very much improved\", \"much improved\", \"minimally improved\", \"no change\", \"minimally worse\", \"much worse\", or \"very much worse\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"23","spread":null},{"groupId":"OG003","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Parent/Caregiver Global Evaluations of the Patient's Overall Change in Symptoms.","description":"The parent/caregiver was asked to rate the patient's overall change in symptoms and overall change in seizure activity and Quality of Life since the beginning of clobazam treatment by checking \"very much improved\", \"much improved\", \"minimally improved\", \"no change\", \"minimally worse\", \"much worse\", or \"very much worse\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"11","spread":null},{"groupId":"OG003","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"18","spread":null},{"groupId":"OG003","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"11","spread":null},{"groupId":"OG003","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Reduction in the Number of Non-drop Seizures.","description":"This outcome measure evaluated the percent reduction (average per week) in non-drop Seizures. Non-drop seizures were other seizures not meeting the drop seizure definition. Drop seizures were defined as a drop attack or spell (atonic, tonic or myoclonic) involving the entire body, trunk, or head that led to a fall, injury, slumping in chair, or head hitting surface or that could have led to a fall or injury, depending on the position of the patient at the time of the attack or spell.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-53.3","spread":null},{"groupId":"OG001","value":"-3.3","spread":null},{"groupId":"OG002","value":"40.0","spread":null},{"groupId":"OG003","value":"-76.3","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Reduction of Total (Drop and Non-Drop) Seizures.","description":"This outcome measure evaluated the percent reduction in average weekly rate in total (drop and non-drop) seizures. Drop seizures were defined as a drop attack or spell (atonic, tonic or myoclonic) involving the entire body, trunk, or head that led to a fall, injury, slumping in chair, or head hitting surface or that could have led to a fall or injury, depending on the position of the patient at the time of the attack or spell. Non-drop seizures were other seizures not meeting the drop seizure definition.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.8","spread":null},{"groupId":"OG001","value":"45.3","spread":null},{"groupId":"OG002","value":"65.3","spread":null},{"groupId":"OG003","value":"9.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":58},"commonTop":["Somnolence","Upper respiratory tract infection","Pyrexia","Nasopharyngitis","Lethargy"]}}}